News Feed
FDA announcements, CT.gov results updates, and commentary from ProgramSignal — automatically linked to programs in our database.
Ono Pharmaceutical's ONO-4578-08 trial has reported positive Phase 2 results at ASCO 2026, with the primary PFS endpoint met at a hazard ratio of 0.67 — ahead of the ProgramSignal consensus prediction of 0.73. ORR of 62.0% in the treatment arm also exceeded the neutral consensus estimate. An interim OS signal (HR 0.60) is directionally strong but immature; the OS endpoint remains open on ProgramSignal pending a mature data cut. Predictions on PFS and ORR have now been scored.
✦ ProgramSignal note: PFS HR and ORR endpoints have been resolved and predictions scored. The OS endpoint remains open — update your view as follow-up data matures.
ClinicalTrials.gov has published results for NCT04617275. Click to view the full results section.
ClinicalTrials.gov has published results for NCT05096221. Click to view the full results section.
ClinicalTrials.gov has published results for NCT04077437. Click to view the full results section.
ClinicalTrials.gov has published results for NCT03574597. Click to view the full results section.
ClinicalTrials.gov has published results for NCT04184622. Click to view the full results section.
ClinicalTrials.gov has published results for NCT04287985. Click to view the full results section.
ClinicalTrials.gov has published results for NCT04191499. Click to view the full results section.
ClinicalTrials.gov has published results for NCT04685135. Click to view the full results section.
ClinicalTrials.gov has published results for NCT05740566. Click to view the full results section.
ClinicalTrials.gov has published results for NCT05107492. Click to view the full results section.